NEC Baby Formula Lawsuit 2026: Similac, Enfamil, and the Premature Infant Litigation

In every NICU in the United States, a critical feeding decision confronts neonatologists: when a premature infant’s mother cannot provide enough breast milk, what formula goes into the feeding tube? For decades, the answer for premature infants has frequently been Similac Special Care or Enfamil Premature — cow-milk based formulas engineered to the higher caloric and protein needs of premature babies.

What the manufacturers of those products did not prominently warn about, according to thousands of families now in litigation, is that cow-milk based formulas carry a meaningfully higher risk of necrotizing enterocolitis — a catastrophic intestinal condition — compared to human donor milk. MDL 3026 is where that argument is being tested in federal court.

What NEC Actually Does to a Premature Infant

Necrotizing enterocolitis does not present subtly. The intestinal wall becomes inflamed, bacteria invade tissue that has been compromised by ischemia, and necrosis — tissue death — spreads. In severe cases, the intestine perforates, releasing bacteria into the abdominal cavity. The resulting sepsis is frequently fatal.

NEC is one of the leading causes of death in premature infants who survive the initial delivery and early stabilization period. Mortality rates in severe cases (Bell Stage III) exceed 30% even with modern NICU interventions. Among survivors, approximately one-quarter require surgical intestinal resection — meaning a portion of the bowel is permanently removed — which can cause short bowel syndrome, a condition requiring lifelong nutritional management and, in the most severe cases, intestinal transplantation.

Infants born before 32 weeks gestation and weighing less than 1,500 grams (very low birth weight) face the highest risk. These are exactly the infants for whom specialized premature formulas like Similac Special Care and Enfamil Premature were designed.

The Scientific Evidence That Drives the Litigation

The core scientific claim in MDL 3026 is not novel. It has been building in peer-reviewed literature for over two decades.

A landmark 1990 study published in The Lancet by Lucas and Cole found a six-fold increase in NEC among exclusively formula-fed premature infants compared to those fed expressed breast milk. Subsequent randomized trials and meta-analyses have consistently found elevated NEC rates among formula-fed premature infants, though the magnitude of the effect has been debated.

What changed the litigation landscape was the 2012 American Academy of Pediatrics policy statement in Pediatrics (the journal of the AAP, which is as close to primary authoritative guidance as neonatology gets): the Academy recommended pasteurized donor human milk “as the optimal source of nutrition for premature and other high-risk infants” when mother’s milk is unavailable — specifically citing decreased NEC risk as a key reason.

In other words, the medical establishment had issued clear guidance favoring human milk for premature infants years before most of these lawsuits were filed — guidance the formula manufacturers did not incorporate into their product labeling or their marketing materials to NICUs.

MDL 3026: What the Federal Litigation Looks Like

The Judicial Panel on Multidistrict Litigation created MDL 3026 — In re Preterm Infant Nutrition Products Liability Litigation — and assigned it to the Northern District of Illinois. The Northern District of Illinois is a major MDL venue with sophisticated management protocols for complex products liability cases.

The federal docket runs parallel to a substantial Illinois state court litigation that has already produced trial verdicts. The relationship between the two tracks is important for plaintiffs to understand:

Track	Court	Status (May 2026)
MDL 3026	N.D. Ill. (Federal)	Active pretrial proceedings; discovery ongoing
Illinois State Court	Cook County Circuit Court	Multiple verdicts; Bellwether trials have proceeded
Other State Courts	Various	Individual cases proceeding under state court rules

The state court verdicts — including substantial plaintiff verdicts in Cook County — have been important signal events. Defense verdicts have also occurred. The mixed results are typical of early-stage mass tort litigation where jury response to complex scientific causation evidence is being tested.

The Failure-to-Warn Theory in Detail

Products liability law in the United States recognizes three main defect theories: manufacturing defect, design defect, and failure to warn. The NEC formula cases primarily run on failure to warn.

The argument is not that cow-milk based premature formula is incapable of nourishing a premature infant — it plainly can. The argument is that the formulas are materially more dangerous than the alternative (donor human milk) for the specific population (very premature, very low birth weight infants) for whom they are primarily marketed, and that this differential risk was known to the manufacturers and not disclosed.

Under the Restatement (Third) of Torts: Products Liability § 2(c), a product is defective because of inadequate warnings “when the foreseeable risks of harm posed by the product could have been reduced or avoided by the provision of reasonable instructions or warnings by the seller.” Plaintiffs argue the scientific literature was sufficient to require disclosure well before the NEC diagnoses in these cases.

Abbott and Mead Johnson contest this vigorously. Their primary defenses include:

• The science was not settled at the time of sale — the link between formula and NEC in premature infants was contested, not established
• Product labeling already directed use under physician supervision; the NICU itself made the feeding decision
• Learned intermediary doctrine: the physician — not the manufacturer — had the duty to inform the patient
• Donor human milk was not always practically available in the quantities NICUs needed

The learned intermediary doctrine is the defense’s strongest card. Under this doctrine, recognized in most states, a drug or medical product manufacturer discharges its duty to warn by informing the prescribing or treating physician, not the patient directly. Plaintiffs respond that the doctrine was developed for prescription drugs, not consumer products marketed directly to hospitals with aggressive sales forces.

Worked Scenario 1 — The Classic NICU Case

A mother delivers twin boys at 28 weeks gestation at a regional hospital in Ohio. Her milk production is delayed and insufficient for two premature infants in the first week. The NICU physician orders Enfamil Premature as supplemental feeding. At 18 days of life, one twin develops abdominal distension, bloody stools, and pneumatosis intestinalis on X-ray — classic NEC presentation. He undergoes emergency surgery; approximately 15 cm of bowel is resected. He survives but develops short bowel syndrome requiring TPN (total parenteral nutrition) for two years and ongoing nutritional monitoring.

The family’s attorney files a failure-to-warn claim against Mead Johnson in federal court in Ohio. The case is transferred to MDL 3026. Discovery produces Mead Johnson’s internal marketing materials to NICUs, sales representative visit logs to the hospital, and internal research files regarding NEC risk data. The attorney retains a neonatologist as a causation expert and a failure-to-warn expert to address what the labeling should have said. Mead Johnson’s learned intermediary defense is tested at a Daubert hearing.

Worked Scenario 2 — The Wrongful Death Case

A family in Georgia delivers a daughter at 27 weeks. Over the first two weeks in the NICU, she is fed Similac Special Care because the hospital’s donor milk bank supply was insufficient. She develops fulminant NEC at three weeks of life. Despite maximal surgical intervention, she dies at six weeks of age. The parents file a wrongful death action under Georgia’s wrongful death statute (O.C.G.A. § 51-4-2) and products liability claim against Abbott. The case transfers to MDL 3026. The damages model includes the full value of the child’s life under Georgia’s full value of life standard, plus the parents’ medical costs. Punitive damages are sought based on evidence that Abbott’s internal files contained NEC risk analyses that were not disclosed to NICUs.

Worked Scenario 3 — The Late-Filing Issue

A family in Texas whose child survived NEC with significant complications learns about the MDL litigation in 2025 — more than three years after the 2021 NICU stay. Texas has a two-year statute of limitations for products liability claims (Tex. Civ. Prac. & Rem. Code § 16.003). Their attorney argues: (1) the discovery rule — the parents did not know and could not reasonably have discovered the formula-NEC connection until they read a 2024 news article about the MDL; (2) fraudulent concealment — Abbott’s failure to disclose internal risk data prevented earlier awareness; and (3) the child’s minority tolling (Tex. Civ. Prac. & Rem. Code § 16.001) — the child’s own claim does not accrue until age 18. The court’s ruling on discovery rule tolling will determine whether the case proceeds.

What Families Should Do Now

If your premature infant was diagnosed with NEC after being fed Similac Special Care or Enfamil Premature in a NICU:

Gather and preserve:

• NICU discharge summary and all medical records (request from hospital medical records department)
• Feeding logs from the NICU stay — what formula, what quantity, for how many days
• Surgical operative reports if your child had intestinal surgery
• All bills and explanation of benefits from your insurer
• Photographs and any video of your child during the NICU stay

Do not:

• Sign any release of claims with the hospital, formula company, or their insurer without attorney review
• Assume your claim is time-barred without getting a legal opinion on tolling

Contact an attorney who handles NEC cases — this is specialized products liability litigation, not a general personal injury practice. Attorneys handling MDL 3026 cases can tell you within a consultation whether your case falls within the litigation parameters.

How the NEC Case Connects to Other Litigation

The NEC formula litigation sits within a broader landscape of product liability cases involving consumer products that carried undisclosed risks. The methodology — failure to warn, learned intermediary contests, Daubert battles over scientific causation — mirrors what happened in Roundup (glyphosate) litigation MDL 2741, where Bayer/Monsanto faced similar arguments about suppressed internal research.

The wrongful death dimension connects this case to birth injury malpractice and cerebral palsy birth injury litigation — all cases where the most catastrophic harm happened in a medical setting to a vulnerable infant. Parents navigating the formula litigation should also understand how mass tort settlements distribute and whether lawsuit proceeds are taxable under IRS § 104.

The Science Will Be Decided in Court — But the Evidence Is Substantial

Defendants will argue at trial that NEC is a multifactorial disease, that premature birth itself is the primary risk factor, and that attributing any individual infant’s NEC to formula rather than prematurity is speculative. These are legitimate scientific points that plaintiffs must overcome with expert testimony meeting Daubert standards.

What plaintiffs have going for them is an extraordinary combination: AAP guidance recommending against cow-milk formula for this specific population, decades of peer-reviewed literature documenting elevated NEC rates in formula-fed premature infants, and early trial verdicts suggesting at least some juries find the failure-to-warn argument persuasive.

The litigation is active. If your family was affected, time is a factor.

The NICU’s Role — And Why It Is Not the Defendant Here

Families sometimes ask whether the hospital or NICU physician is liable for the feeding decision. The NEC formula litigation is specifically structured as a product liability case against manufacturers — not a malpractice case against the NICU.

This is an important distinction with strategic implications:

Why manufacturers, not doctors: The failure-to-warn theory places responsibility on Abbott and Mead Johnson for not disclosing known risks through product labeling and marketing materials. The NICU physician made a clinical decision with the information available — information the plaintiff argues was inadequate because the manufacturer concealed or downplayed the NEC risk differential.

The learned intermediary response: Manufacturers will argue they provided the NICU physicians (the “learned intermediaries”) with sufficient information to make the feeding decision, and that any failure to use donor human milk was a clinical judgment by the NICU. Plaintiffs counter that learned intermediary doctrine does not protect a manufacturer who actively markets products to hospitals while suppressing adverse risk data.

Parallel malpractice evaluation: Nothing prevents a family from also having a medical malpractice attorney evaluate the NICU’s feeding protocol decisions. These are separate claims against separate defendants. However, malpractice claims carry their own challenges — expert testimony requirements, medical review panel requirements in some states, and the generally high standard for proving physician negligence.

What the Hospital’s Formula Formulary Means for Your Case

In most NICUs, formula selection is not made by the bedside nurse or even the attending neonatologist on an individual-patient basis. It reflects a formulary decision — the hospital’s approved list of products, selected by a pharmacy and therapeutics committee in consultation with neonatology staff.

This formulary structure is both a legal asset and a challenge for plaintiffs:

Asset: It shows the hospital was receiving marketing from the formula companies, creating a direct commercial relationship. Sales representative visit logs subpoenaed in litigation often show aggressive outreach by Abbott and Mead Johnson sales staff, including presentations that emphasized nutritional benefits without disclosing NEC risk comparisons.

Challenge: It creates a sophisticated intermediary between the manufacturer and the patient — the hospital’s purchasing and formulary committee, staffed by medical professionals. Defendants argue this committee was capable of independently evaluating the literature, further supporting the learned intermediary defense.

Plaintiffs respond by documenting the information asymmetry: the formulary committee was presented with manufacturer-funded studies emphasizing benefit and was not provided internal manufacturer research showing elevated NEC risk. This is the same structure that produced liability findings in pharmaceutical failure-to-warn cases like In re Vioxx Products Liability Litigation (E.D. La.) — where manufacturer suppression of internal research undermined the learned intermediary defense.

How NEC Damages Are Calculated

The economic damages in NEC cases can be substantial, particularly in cases involving severe complications or wrongful death:

Damage Category	What It Includes
Past Medical Expenses	NICU stay, NEC surgery, ICU care, ostomy care, post-discharge treatment
Future Medical Expenses	Ongoing intestinal rehabilitation, nutritional support (TPN), potential re-operations, developmental therapy
Lost Earning Capacity (child)	Present value of lifetime earnings reduced by early death or permanent disability
Parental Lost Wages	Time missed from work during NICU stay and following discharge for caretaking
Pain and Suffering (infant)	The infant’s pre-death or ongoing physical suffering — quantified through medical records
Parental Emotional Distress	Varies by state; some states allow bystander liability for parents who witnessed the medical crisis
Wrongful Death	Under state wrongful death statutes — value of child’s life, parental grief where state allows
Punitive Damages	Where manufacturer conduct meets the state’s willfulness/malice standard

Medical economic experts calculate future care costs based on published cost tables for pediatric intestinal rehabilitation programs. Life care planners document the anticipated lifetime needs of a child who survived NEC with short bowel syndrome. These experts are critical to maximizing the economic damages portion of a case.

The Role of Donor Human Milk Banks

One issue defendants raise consistently: was donor human milk actually available as an alternative?

The Mothers’ Milk Bank network — operated through the Human Milk Banking Association of North America (HMBANA) — has grown substantially over the past decade. As of 2025, HMBANA-affiliated banks operate in approximately 30 states, and the number of NICUs with established donor milk protocols has increased.

However, in 2015 and earlier — when many of the MDL 3026 plaintiffs’ NICU stays occurred — donor milk availability was substantially more limited. Some NICUs had no established donor milk program. Others had programs that could not supply sufficient volume for all premature infants who needed supplemental feeding.

Plaintiffs argue that the availability issue is irrelevant to the failure-to-warn claim: even if donor milk was not available in a particular NICU at a particular time, the manufacturers still had a duty to disclose the NEC risk comparison in their labeling, which would have enabled clinicians and families to make informed decisions and potentially advocate for donor milk access.

Regulatory History: What the FDA Knew

The FDA has not issued a specific safety communication about cow-milk premature formula and NEC risk. This silence cuts both ways in litigation:

Defendants point to FDA inaction as evidence that the scientific evidence is insufficient to require a warning — the regulatory agency reviewed the same scientific literature and did not require labeling changes.

Plaintiffs counter that FDA inaction reflects the agency’s limited resources for proactive label review and does not constitute affirmative approval. Courts have consistently held that FDA clearance or approval does not preempt state failure-to-warn tort claims. In Wyeth v. Levine (2009), the Supreme Court held (9-0) that FDA approval of a drug’s labeling does not preempt a state law failure-to-warn claim, and that manufacturers can strengthen warnings without prior FDA approval. This ruling is central to why NEC formula plaintiffs can proceed in tort even though FDA has not required label changes.

What Families Should Realistically Expect From the Litigation

The NEC formula litigation is at a pivotal stage. The federal MDL 3026 is actively proceeding with discovery. State court verdicts — mixed between plaintiff and defense outcomes — have established that juries can be persuaded on these facts and that the defense has viable counterarguments.

Families considering filing should understand:

1. Timeline: Large products liability MDLs take three to seven years to reach resolution. This is a long-term commitment.
2. Expert battles: General causation will be heavily contested. Not every plaintiff’s case survives Daubert challenges in federal court.
3. Individual case facts matter: Cases with clear, documented NEC diagnosis, NICU records confirming formula use, and serious resulting harm (surgery, death) are strongest. Cases where the diagnosis is uncertain or the formula connection is weak face harder paths.
4. No global settlement yet: As of May 2026, no settlement fund has been announced. Recovery, if it comes, is likely years away.
5. Contingency representation: Attorneys take these cases on contingency — no upfront cost. Evaluate the attorney’s experience with NEC cases specifically before engaging.

---

This post is for informational purposes only and does not constitute legal advice. Statutes of limitations and case-specific facts require evaluation by a licensed attorney in your jurisdiction.